DelveInsight’s, “Castrate Resistant Prostrate Cancer Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook
Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report
- In September 2024:- Bayer– A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).
- DelveInsight’s Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
- The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
- Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs
Castrate Resistant Prostrate Cancer Emerging Drugs
- Niraparib: Janseen
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
- Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers
Scope of the Castrate Resistant Prostrate Cancer Pipeline Report
- Coverage- Global
- Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
- Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
- Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Castrate Resistant Prostrate Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Castrate Resistant Prostrate Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Castrate Resistant Prostrate Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Niraparib: Janseen
- Mid Stage Products (Phase II)
- ZEN003694: Newsoara Biopharma
- Early Stage Products (Phase I)
- EPI7386: ESSA Pharma
- Pre-clinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Castrate Resistant Prostrate Cancer Key Companies
- Castrate Resistant Prostrate Cancer Key Products
- Castrate Resistant Prostrate Cancer- Unmet Needs
- Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
- Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
- Castrate Resistant Prostrate Cancer Analyst Views
- Castrate Resistant Prostrate Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024